Antibody-Drug Conjugates: Ushering in a New Era of Cancer Therapy.

ABSTRACT: Antibody-drug conjugates (ADCs) have provided new therapeutic options and significant promise for patients with cancer, particularly where existing treatments are limited. Substantial effort in ADC development is underway globally, with 13 ADCs currently approved and many more in development. The therapeutic benefits of ADCs leverage the ability to selectively target cancer cells through antibody binding, resultant relative sparing of non-malignant tissues, and the targeted delivery of a cytotoxic payload. Consequently, this drug class has demonstrated activity in multiple malignancies refractory to standard therapeutic options. Despite this, limitations exist, including narrow therapeutic windows, unique toxicity profiles, development of therapeutic resistance, and appropriate biomarker s

SUBMITTER: Hurwitz J 

PROVIDER: S-EPMC10458257 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature